121 related articles for article (PubMed ID: 38546663)
21. Surgical results of metastatic spinal cord compression (MSCC) from non-small cell lung cancer (NSCLC): analysis of functional outcome, survival time, and complication.
Park SJ; Lee CS; Chung SS
Spine J; 2016 Mar; 16(3):322-8. PubMed ID: 26586194
[TBL] [Abstract][Full Text] [Related]
22. Comparing Physician and Nurse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Ratings as Predictors of Clinical Outcomes in Patients with Cancer.
Neeman E; Gresham G; Ovasapians N; Hendifar A; Tuli R; Figlin R; Shinde A
Oncologist; 2019 Dec; 24(12):e1460-e1466. PubMed ID: 31227648
[TBL] [Abstract][Full Text] [Related]
23. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status.
Azad AA; Eigl BJ; Leibowitz-Amit R; Lester R; Kollmannsberger C; Murray N; Clayton R; Heng DY; Joshua AM; Chi KN
Eur Urol; 2015 Mar; 67(3):441-7. PubMed ID: 24508071
[TBL] [Abstract][Full Text] [Related]
24. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status.
Alessi JV; Ricciuti B; Jiménez-Aguilar E; Hong F; Wei Z; Nishino M; Plodkowski AJ; Sawan P; Luo J; Rizvi H; Carter BW; Heymach JV; Altan M; Hellmann M; Awad M
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753547
[TBL] [Abstract][Full Text] [Related]
25. CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations.
Felip E; Ardizzoni A; Ciuleanu T; Cobo M; Laktionov K; Szilasi M; Califano R; Carcereny E; Griffiths R; Paz-Ares L; Duchnowska R; Garcia MA; Isla D; Jassem J; Appel W; Milanowski J; Van Meerbeeck JP; Wolf J; Li A; Acevedo A; Popat S
Eur J Cancer; 2020 Mar; 127():160-172. PubMed ID: 32028209
[TBL] [Abstract][Full Text] [Related]
26. Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer.
Leung EY; Scott HR; McMillan DC
J Thorac Oncol; 2012 Apr; 7(4):655-62. PubMed ID: 22425914
[TBL] [Abstract][Full Text] [Related]
27. Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment.
Käsmann L; Taugner J; Eze C; Roengvoraphoj O; Dantes M; Gennen K; Karin M; Petrukhnov O; Tufman A; Belka C; Manapov F
Anticancer Res; 2019 Sep; 39(9):5077-5081. PubMed ID: 31519618
[TBL] [Abstract][Full Text] [Related]
28. Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153).
Spigel DR; McCleod M; Jotte RM; Einhorn L; Horn L; Waterhouse DM; Creelan B; Babu S; Leighl NB; Chandler JC; Couture F; Keogh G; Goss G; Daniel DB; Garon EB; Schwartzberg LS; Sen R; Korytowsky B; Li A; Aanur N; Hussein MA
J Thorac Oncol; 2019 Sep; 14(9):1628-1639. PubMed ID: 31121324
[TBL] [Abstract][Full Text] [Related]
29. Differences in Performance Status Assessment Among Palliative Care Specialists, Nurses, and Medical Oncologists.
Kim YJ; Hui D; Zhang Y; Park JC; Chisholm G; Williams J; Bruera E
J Pain Symptom Manage; 2015 Jun; 49(6):1050-1058.e2. PubMed ID: 25542550
[TBL] [Abstract][Full Text] [Related]
30. Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non-Small-Cell Lung Cancer in the United States.
Stenehjem DD; Lubinga SJ; Gupte-Singh K; Zhang Y; Le TK; Penrod JR; Smith CB
Clin Lung Cancer; 2021 Jan; 22(1):e35-e47. PubMed ID: 33187914
[TBL] [Abstract][Full Text] [Related]
31. Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population.
Jiménez Galán R; Prado-Mel E; Pérez-Moreno MA; Caballano-Infantes E; Flores Moreno S
Biology (Basel); 2021 Sep; 10(9):. PubMed ID: 34571767
[TBL] [Abstract][Full Text] [Related]
32. Should patient-rated performance status affect treatment decisions in advanced lung cancer?
Dajczman E; Kasymjanova G; Kreisman H; Swinton N; Pepe C; Small D
J Thorac Oncol; 2008 Oct; 3(10):1133-6. PubMed ID: 18827609
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy with toripalimab for lung adenocarcinoma in a real-world patient with an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 4: a case report.
Xue Y; Zheng K; Xue J
Ann Palliat Med; 2021 Sep; 10(9):10114-10123. PubMed ID: 34628932
[TBL] [Abstract][Full Text] [Related]
34. FACT-Hep increases the accuracy of survival prediction in HCC patients when added to ECOG Performance Status.
Gmür A; Kolly P; Knöpfli M; Dufour JF
Liver Int; 2018 Aug; 38(8):1468-1474. PubMed ID: 29389088
[TBL] [Abstract][Full Text] [Related]
35. The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy.
Lee SM; Upadhyay S; Lewanski C; Falk S; Skailes G; Woll PJ; Hatton M; Lal R; Jones R; Toy E; Rudd R; Ngai Y; Edwards A; Hackshaw A
Eur J Cancer; 2019 Oct; 120():86-96. PubMed ID: 31499384
[TBL] [Abstract][Full Text] [Related]
36. Interconversion of two commonly used performance tools: An analysis of 5844 paired assessments in 1501 lung cancer patients.
Prasad KT; Kaur H; Muthu V; Aggarwal AN; Behera D; Singh N
World J Clin Oncol; 2018 Nov; 9(7):140-147. PubMed ID: 30425939
[TBL] [Abstract][Full Text] [Related]
37. Use of Wearable Activity Tracker in Patients With Cancer Undergoing Chemotherapy: Toward Evaluating Risk of Unplanned Health Care Encounters.
Nilanon T; Nocera LP; Martin AS; Kolatkar A; May M; Hasnain Z; Ueno NT; Yennu S; Alexander A; Mejia AE; Boles RW; Li M; Lee JSH; Hanlon SE; Cozzens Philips FA; Quinn DI; Newton PK; Broderick J; Shahabi C; Kuhn P; Nieva JJ
JCO Clin Cancer Inform; 2020 Sep; 4():839-853. PubMed ID: 32970482
[TBL] [Abstract][Full Text] [Related]
38. Simple prognostic model for patients with advanced cancer based on performance status.
Jang RW; Caraiscos VB; Swami N; Banerjee S; Mak E; Kaya E; Rodin G; Bryson J; Ridley JZ; Le LW; Zimmermann C
J Oncol Pract; 2014 Sep; 10(5):e335-41. PubMed ID: 25118208
[TBL] [Abstract][Full Text] [Related]
39. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599.
Langer C; Li S; Schiller J; Tester W; Rapoport BL; Johnson DH;
J Clin Oncol; 2007 Feb; 25(4):418-23. PubMed ID: 17264337
[TBL] [Abstract][Full Text] [Related]
40. Discrepancies between genitourinary cancer patients' and clinicians' characterization of the Eastern Cooperative Oncology Group performance status.
Bergerot CD; Philip EJ; Bergerot PG; Hsu J; Dizman N; Salgia M; Salgia N; Vaishampayan U; Battle D; Loscalzo M; Dale W; Pal SK
Cancer; 2021 Feb; 127(3):354-358. PubMed ID: 33007114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
